机译:更好吗?扩展的替莫唑胺辅助治疗对新诊断的胶质母细胞瘤的影响:EORTC和NRG肿瘤学/ RTOG的二级分析
Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel|European Org Res Treatment Canc, Brussels EORTC, Brussels, Belgium;
European Org Res Treatment Canc, Brussels EORTC, Brussels, Belgium;
Univ Alabama Birmingham, Birmingham, AL USA;
Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada;
Lausanne Univ Hosp, Lausanne, Switzerland;
NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA;
European Org Res Treatment Canc, Brussels EORTC, Brussels, Belgium;
Univ Toronto, Odette Canc Ctr, Toronto, ON, Canada|Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada;
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea;
Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland;
Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel;
Lausanne Univ Hosp, Lausanne, Switzerland;
Mayo Clin, Rochester, MN USA;
Univ Bonn, Med Ctr, Robert Janker Clin, Bonn, Germany|Maastricht Univ, Med Ctr, MAASTRO Clin, GROW Sch Oncol, Maastricht, Netherlands;
Miami Canc Inst, Miami, FL USA;
Erasmus Univ Hosp, Rotterdam, Netherlands;
Dana Farber Canc Inst, Boston, MA 02115 USA|Harvard Med Sch, Boston, MA USA;
Univ Zurich, Zurich, Switzerland;
Lausanne Univ Hosp, Lausanne, Switzerland|Univ Zurich, Zurich, Switzerland;
机译:RTOG 0834 / EORTC 26053-22054 / NCIC CTG CEC.1 / CATNON杂项试验的放射疗法质量保证“新诊断的非1P / 19Q缺失的内塑性胶质瘤同时和佐剂替替替莫替莫替斯化疗”:个人案例审查分析
机译:放射治疗肿瘤学0525组的临床净收益分析:Ⅲ期试验,比较新诊断的成胶质细胞瘤患者常规替莫唑胺和剂量密集型替莫唑胺
机译:依维莫司联合化学放疗在新诊断的胶质母细胞瘤中的随机II期研究:NRG肿瘤学RTOG 0913的结果
机译:风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松,用于新诊断的未经治疗的全身淀粉样蛋白症患者:II期试验的中期报告
机译:教育注册护士如何为新诊断的儿科肿瘤患者实施生育保护方法
机译:更好吗?扩展的替莫唑胺辅助治疗对新诊断的胶质母细胞瘤的影响:EORTC和NRG肿瘤学/ RTOG的二级分析
机译:更好吗?延伸辅助替替唑粒子在新诊断的胶质细胞瘤中的影响:EORTC和NRG肿瘤学的二次分析/ RTOG